Attributes | Values |
---|
rdf:type
| |
description
| - artículu científicu espublizáu en 1999 (ast)
- vědecký článek publikovaný v roce 1999 (cs)
- 1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած (hyw)
- наукова стаття, опублікована в грудні 1999 (uk)
- vedecký článok (publikovaný 1999/12/01) (sk)
- مقالة علمية (نشرت في ديسمبر 1999) (ar)
- 1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված (hy)
- article scientifique publié en 1999 (fr)
- im Dezember 1999 veröffentlichter wissenschaftlicher Artikel (de)
- scientific journal article (en)
- wetenschappelijk artikel (gepubliceerd op 1999/12/01) (nl)
|
publication date
| |
publication date
| |
language of work or name
| |
language of work or name
| |
author name string
| |
OpenCitations bibliographic resource ID
| |
OpenCitations bibliographic resource ID
| |
author name string
| - G. Xu
- D. A. Stoffers
- S. Bonner-Weir
|
OpenCitations bibliographic resource ID
| |
rdfs:label
| - Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (en)
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (nl)
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (ast)
|
skos:prefLabel
| - Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (en)
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (nl)
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (ast)
|
name
| - Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (en)
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (nl)
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (ast)
|
author
| |
author
| |
title
| |
title
| - Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |
DOI
| |
DOI
| |
DOI
| - 10.2337/DIABETES.48.12.2270
|
ResearchGate publication ID
| |
ResearchGate publication ID
| |
is about
of | |
is cites work
of | - In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow
- Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells
- Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function
- Expression of the GLP-1 receptor in mouse, rat, and human pancreas
- Metabolic programming: causes and consequences
- The toll-like receptor signaling molecule Myd88 contributes to pancreatic beta-cell homeostasis in response to injury
- Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system
- Incretins, insulin secretion and Type 2 diabetes mellitus
- Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes
- Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration
- Safety and adverse effects associated with GLP-1 analogues
- Incretin mimetics as emerging treatments for type 2 diabetes
- Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats
- A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice
- Stem cell therapy to treat diabetes mellitus
- Enhanced expression of VEGF-A in β cells increases endothelial cell number but impairs islet morphogenesis and β cell proliferation.
- Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss
- Regulation of pancreatic beta-cell mass
- Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth
- Type 1 diabetes: etiology, immunology, and therapeutic strategies
- Preexisting pancreatic acinar cells contribute to acinar cell, but not islet beta cell, regeneration.
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
- The rise and fall of insulin secretion in type 1 diabetes mellitus
- Functional effects of expression of wolframin-antisense transcripts in BRIN-BD11 β-cells
- Identification and expansion of pancreatic stem/progenitor cells.
- Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors
- Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function
- The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice
- Glucagon-like peptide analogues for type 2 diabetes mellitus
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
- Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice
- Enhancing Incretin Action for the Treatment of Type 2 Diabetes
- Insulin-producing cells generated from dedifferentiated human pancreatic beta cells expanded in vitro
- A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
- Potential new treatments for type 2 diabetes
- Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice
- Evolution of exenatide as a diabetes therapeutic
- Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis
- A simple matter of life and death-the trials of postnatal Beta-cell mass regulation
- A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-cell survival and function.
- Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan
|